Smith+Nephew $1 billion notes offering
Davis Polk advised Smith & Nephew plc in connection with the establishment of a WKSI shelf and its debut SEC-registered shelf takedown of $1 billion aggregate principal amount of 2.032%…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Aziyo Biologics $50 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $50 million initial public offering of common stock by Aziyo Biologics, Inc. The common stock…
NanoString Technologies $216.2 million follow-on offering
Davis Polk advised the joint book-running managers in connection with a $216.2 million public offering of 5,750,000 shares of common stock by NanoString Technologies, Inc., which…
Owens & Minor $200 million follow-on offering
Davis Polk advised the joint book-running managers and representatives to the underwriters in connection with the approximately $200 million follow-on public offering of…
Beam Therapeutics $127 million offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…
Biondvax Pharmaceuticals $100 million at-the-market offering
Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …
Gilead Sciences $7.25 billion senior notes offering
Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…
Hologic $950 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $950 million aggregate principal amount of its…
Medtronic Global Holdings €6.25 billion notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €6.25 billion aggregate principal amount of notes by Medtronic Global…
ADC Therapeutics $204 million SEC-registered offering
Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…